Faculty

Back to Index
Jonathan S Lopresti, MD
Associate Professor of Clinical Medicine
Medicine
BMT B11 Health Sciences Campus Los Angeles
+1 323 226 4632

Overview

A native of Los Angeles, Dr. LoPresti received both his medical degree and his Ph.D. in physiology from the University of Southern California. He first joined the Trojan family in 1974 as a biology undergraduate and finished his residency at the LAC+USC Medical Center ten years later. Dr. LoPresti has contributed to over fifty presentations, recently lecturing on a case of an aggressive Papillary Thyroid Cancer arising in the third trimester of pregnancy. In addition, he has had leadership roles in the American Thyroid Association and has been published in numerous journals, abstracts and book chapters.

Awards

Keck School of Medicine of USC: Professor of the Year for Fourth Year Students, 1998

Keck School of Medicine of USC: Faculty Teaching Award, Year II, 2015

Department of Medicine, USC: Attending of the Year for Internal Medicine, 1997

Keck School of Medicine of USC: Faculty Teaching Award, Year IV, 2015

Publications

Angell TE, Lechner MG, Nguyen CT, Salvato VL, Nicoloff JT, LoPresti JS. Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study. J Clin Endocrinol Metab. 2015 Feb; 100(2):451-9. View in: PubMed

Spencer C, Petrovic I, Fatemi S, LoPresti J. Serum thyroglobulin (tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications. J Clin Endocrinol Metab. 2014 Dec; 99(12):4589-99. View in: PubMed

Angell TE, Lechner MG, Jang JK, LoPresti JS, Epstein AL. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res. 2014 Dec 1; 20(23):6034-44. View in: PubMed

Kaptein EM, LoPresti JS, Kaptein MJ. Is an Isolated TSH Elevation in Chronic Nonthyroidal Illness "Subclinical Hypothyroidism"? J Clin Endocrinol Metab. 2014 Nov; 99(11):4015-26. View in: PubMed

Spencer C, LoPresti J, Fatemi S. How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies. Curr Opin Endocrinol Diabetes Obes. 2014 Oct; 21(5):394-404. View in: PubMed

Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL. BRAF(V600E) in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration. Thyroid. 2014 Sep; 24(9):1385-93. View in: PubMed

Angell TE, Spencer CA, Rubino BD, Nicoloff JT, LoPresti JS. In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation. Thyroid. 2014 Jul; 24(7):1127-33. View in: PubMed

Spencer C, Fatemi S, Singer P, Nicoloff J, Lopresti J. Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid. 2010 Jun; 20(6):587-95. View in: PubMed

Spencer CA, Lopresti JS. Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat Clin Pract Endocrinol Metab. 2008 Apr; 4(4):223-33. View in: PubMed

Fatemi S, LoPresti JS. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003 Sep; 88(9):4507-8; author reply 4508-10. View in: PubMed

Powered bySC CTSI